

BC Cancer ST Program Updates for October 2026

AFFECTED APPLICATION(S)	PowerChart
AFFECTED AREA(S)	BC Cancer Sites / VCH Oncology Sites
NET NEW, OR UPDATE TO EXISTING BUILD	Update to Existing Build


What has Changed?

Any changes released that affect Oncology Regimens and PowerPlans/Cycles for the **BC Cancer Systemic Therapy (ST) Program** will be communicated monthly via Special Bulletin.

These notification changes are important for Nursing staff, Pharmacy, and Providers to be aware of for their patient's care.

For Providers:

- For PowerPlans that are versioned: If your patient has already started on a Regimen, when you order the next cycle PowerPlan, a pop-up window will appear to indicate a new version is required.
 - Click Yes to accept the new version.
 - Do not** use the Copy Forward functionality to ensure that the updates apply.



- IMPORTANT:** Any change from the standard treatment regimen (dose modification, addition of premed, etc.) in the previous cycle will need to be manually added to the cycle that is being ordered with the new version (see additional documentation regarding versioning).

Please see this month's changes below.

Protocols: GITREMDUR

Cycles/PowerPlans: Cycle 1 PowerPlan

Changes:

In the Chemotherapy Phase:

- Teal CDS note updated to "Patients to be observed for one hour after tremelimumab infusion"
- Durvalumab offset updated to +120 min

ONCP GI GITREMDUR Cycle 1 - Cycle 1, Chemotherapy (Day 1) (Future Pending) *Est. 18-Sep-202	
Component	Day 1
	Future Pending
	*Est. 18-Sep-2026 08:...
	Actions
Treatment Regimen	
☒ Zero Time	0 hr
	Planned
Vital signs immediately before the start of tremelimumab infusion, at 30 minutes into the infusion, at end of infusion, and as needed	
Use separate infusion line and filter for each drug	
☒ tremelimumab (tremelimumab - oncology)	0 min
300 mg, IV, once oncology, administer over: 60 minute, drug...	
Use a 0.2 micron in-line filter. Day 1	Planned
☒ Patients to be observed for one hour after tremelimumab infusion	
☒ durvalumab (durvalumab - oncology (CAPPED 1500 mg))	+120 min
20 mg/kg, IV, once oncology, administer over: 60 minute, dr...	
Max dose: 1500 mg. Use a 0.2 micron in-line filter. Day 1	Planned

Versioning: Yes

Jira: CST-387411

Protocols: BRAVENH

Cycles/PowerPlans: Associated Regimen and Treatment Plan

Changes:

Regimen Description and Link to Protocol note updated to:

- Palliative Therapy for HER2-Positive Metastatic Breast Cancer using Trastuzumab Deruxtecan (ENHERTU)

ONC BR BRAVENH (Pending)

▼ Hide additional details

Regimen description: Palliative Therapy for HER2-Positive Metastatic Breast Cancer using Trastuzumab Deruxtecan (ENHERTU)

Versioning: Yes

Jira: CST-387414

Protocols: ULUAVPPAMI and ULUAVPPAF

Cycles/PowerPlans: All Associated PowerPlans and Regimens

Changes:

- "Total Bilirubin Less Than or Equal to 1.5 x ULN within 96 hours" removed from Pre-Chemo Metrics
- "Patient to take dexamethasone 8 mg PO BID for 4 doses starting 2 days prior to Cycle 1 Day 1" Clinical Decision Support Note color changed from yellow to teal for all Cycle 1 plans

ONCP LU ULUAVPPAMI Baseline Weight 80 kg or more Cycle 1 - Cycle 1, Chemotherapy (Day 1 to 2, 8, 15) (Future Pending)			
		Day 1	Day 2
	Component	Future Pending	Future Pending
		*Est. 19-Sep-2026 08:...	*Est. 20-Sep-2026 08:...
		Actions ▼	Actions ▼
	Link to Protocol: Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) with CARBOplatin, Pemetrexed and Amivantamab		
	Revised: 1 October 2026		
	Pre-Chemo Metrics		
	May proceed with treatment on Day 1 if:		
	Neutrophils Greater Than or Equal to $1.5 \times 10^9/L$ within 96 hours		
	Platelet Count Greater Than or Equal to $100 \times 10^9/L$ within 96 hours		
	Creatinine Clearance Greater Than or Equal to 45 mL/min within 96 hours		
	Pre-Medications		
	Patient to take own supply of pre-medications. RN/Pharmacist to confirm		
	Ensure patient is taking folic acid and has had vitamin B12 injection starting at least 7 days prior to first cycle, and to continue while on treatment, until 21 days after last pemetrexed dose. Patient to obtain supply		
	Patient to take dexamethasone 8 mg PO BID for 4 doses starting 2 days prior to Cycle 1 Day 1		
	dexamethasone	-20 min	
	8 mg, PO, once oncology, drug form: tab, Use Patient S...		
	Between 30 and 60 minutes prior to CARBOplatin. Day 1	Planned	

Removed "Total Bilirubin Less Than or Equal to 1.5 x ULN within 96 hours"

ONCP LU ULUAVPPAF Baseline Weight 80 kg or more Cycle 1 - Cycle 1, Chemotherapy (Day 1 to 2, 8, 15) (Future Pend			Day 1	Day 2
Component			Future Pending	Future Pending
			*Est. 19-Sep-2026 08:...	*Est. 20-Sep-2026 08:...
			Actions	Actions
Link to Protocol: First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) with CARBOplatin, Pemetrexed and Amivantamab				
Revised: 1 October 2026				
Pre-Chemo Metrics				
May proceed with treatment on Day 1 if:				
Neutrophils Greater Than or Equal to $1.5 \times 10^9/L$ within 96 hours				
Platelet Count Greater Than or Equal to $100 \times 10^9/L$ within 96 hours				
Creatinine Clearance Greater Than or Equal to 45 mL/min within 96 hours				
Pre-Medications				
Patient to take own supply of pre-medications. RN/Pharmacist to confirm				
Ensure patient is taking folic acid and has had vitamin B12 injection starting at least 7 days prior to first cycle of pemetrexed, and to continue while on treatment, until 21 days after last pemetrexed dose. Patient to obtain supply				
Patient to take dexamethasone 8 mg PO BID for 4 doses starting 2 days prior to Cycle 1 Day 1				
dexamethasone			-20 min	
8 mg, PO, once oncology, drug form: tab, Use Patient S...				

Removed "Total Bilirubin Less Than or Equal to $1.5 \times ULN$ within 96 hours"

Versioning: Yes

Jira: CST-385841

Protocols: SAVACM, SCMESNA for SAVACM

Cycles/PowerPlans: All Associated PowerPlans and Regimens

Changes:

Pretreatment Lab phase

- 'If clinically indicated:' Yellow Clinical Decision Support Note added above Electrocardiogram 12 Lead order
- Electrocardiogram 12 Lead order with order sentence T;N, not preselected, added

4 ONCP SA SAVACM (Inpatient) - Cycle 1, Pretreatment Labs (Day 1) (Future Pending) *Est. 21-Sep-2026 08:25 PDT - 21 Days		
Revised: 1 Oct 2026		
If urine positive for blood see supportive care protocol - SCMESNA for SAVACM		
☒	☒ CBC and Differential	Blood, Routine, once, Order for future visit
☒	☒ Creatinine and Estimated GFR	Blood, Routine, once, Order for future visit
☒	☒ Bilirubin Total	Blood, Routine, once, Order for future visit
☒	☒ Alanine Aminotransferase	Blood, Routine, once, Order for future visit
☒	☒ Alkaline Phosphatase	Blood, Routine, once, Order for future visit
☒	☒ Gamma Glutamyl Transferase	Blood, Routine, once, Order for future visit
☒	☒ Lactate Dehydrogenase	Blood, Routine, once, Order for future visit
☒	☒ POC Urinalysis Dipstick	once, Dipstick urine for blood prior to chemo. If positive, notify MD and send urine sample for urinalysis for verification and accurate determination of hem...
If clinically indicated:		
☐	☒ Electrocardiogram 12 Lead	T.N

Chemotherapy phase

- Aprepitant order is now preselected
- “May proceed with doses as written if:” Yellow Clinical Decision Support Note added
- “Neutrophils Greater Than or Equal to 0.75 x 10⁹/L within 48 hours” Yellow Clinical Decision Support Note added
- “Platelets Greater Than or Equal to 100 x 10⁹/L within 48 hours” Yellow Clinical Decision Support Note added
- PO mesna – oncology order comment, Under Treatment Regimen, updated to “Hours 5 and 8. Give in carbonated beverage. Round to nearest 10 mg. Day 1”

4 ONCP SA SAVACM (Inpatient) - Cycle 1, Chemotherapy (Day 1) (Future Pending) *Est. 21-Sep-2026 08:25 PDT - 21 Days		
Link to Protocol: Treatment of Sarcomas with Pelvic Primaries or Chemotherapy-Induced Hematuria using vinCRiStine, DOXOrubicin, Cyclophosphamide and Mesna		
Pre-Medications		
May proceed with doses as written if:		
Neutrophils Greater Than or Equal to 0.75 x 10 ⁹ /L within 48 hours		
Platelets Greater Than or Equal to 100 x 10 ⁹ /L within 48 hours		
☒	☒ ondansetron	8 mg, PO, once oncology, drug form: tab 30 minutes prior to treatment. Day 1
☒	☒ dexamethasone	Select an order sentence
If using aprepitant, order Day 2 and subsequent doses in Chemotherapy Related Orders phase		
☒	☒ aprepitant	125 mg, PO, once oncology, drug form: tab 30 minutes prior to treatment. Day 1
Treatment Regimen		
Zero Time		
If using a peripheral line, infuse vinca alkaloid via gravity only; DO NOT USE an infusion pump		
☒	☒ vinCRiStine (vinCRiStine - oncology)	1.5 mg/m ² , IV, once oncology, administer over: 15 minute, drug form: bag Maximum dose = 2 mg. Hour 0 to 0:15. Day 1
If patient receiving radiation, omit DOXOrubicin		
☒	☒ DOXOrubicin (DOXOrubicin - oncology)	75 mg/m ² , IV, once oncology, drug form: syringe-inj Hour 0:15 to 0:35. Day 1
☒	☒ mesna (mesna - oncology)	240 mg/m ² , IV, once oncology, administer over: 15 minute, drug form: bag Hour 0:35 to 0:50. Day 1
☒	☒ cyclophosphamide (cyclophosphamide - oncology)	1,200 mg/m ² , IV, once oncology, administer over: 60 minute, drug form: bag Hour 0:50 to 1:50. Day 1
☒	☒ dextrose 5%-sodium chloride 0.45% (dextrose 5%-sodium chloride 0.45% (DS-1...	2,250 mL, IV, once oncology, administer over: 9 hour, drug form: bag Hour 1:45 to 11: Rate at 250 mL/hour
Choose mesna IV or PO:		
☐	☒ mesna (mesna - oncology)	240 mg/m ² , IV, q3h oncology, administer over: 15 minute, order duration: 2 doses or times, drug form: bag Hours 5 and 8. Day 1
☐	☒ mesna (mesna - oncology)	480 mg/m ² , PO, q3h oncology, order duration: 2 doses or times, drug form: tab Hours 5 and 8. Give in carbonated beverage. Round to nearest 10 mg. Day 1

4 ONCP SC SCMESNA for SAVACM (Inpatient) - Cycle 1, Chemotherapy (Day 1 to 3) (Future Pending) *Est. 21-Sep-2026 08:41 PDT - 21 Days		
Link to Protocol: MESNA Dosage Modification for Hematuria Secondary to Oxazaphosphorines (e.g. Ifosfamide and Cyclophosphamide)		
Pre-Medications		
☒	☒ ondansetron	8 mg, PO, once oncology, drug form: tab 30 minutes prior to treatment. Day 1
☒	☒ dexamethasone	Select an order sentence
If using aprepitant, reminder to order days 2 and 3 in chemotherapy related orders phase		
☒	☒ aprepitant	125 mg, PO, once oncology, drug form: tab 30 minutes prior to treatment. Day 1

Versioning: Yes

Jira: CST-385569

Protocols: GIATZB, LUAVATZ, LUSCATPE

Cycles/PowerPlans: Cycle 1 PowerPlans

Changes: Scheduling Phase:

- Teal Clinical Decision Note below yellow CDS note "Select one atezolizumab option" added: "Insert peripheral IV and saline lock prior to first administration of atezolizumab subcutaneously for cycle 1 PowerPlans only"
- Teal Clinical Decision Note below the subcutaneous atezolizumab order added: "During treatment with subcutaneous atezolizumab, administer other subcutaneous drugs at alternate injection sites whenever possible"

ONCP LU LUAVATZ Cycle 1 - Cycle 1, Chemotherapy (Day 1) (Future Pending)		
Component	Day 1	Future Pending
Link to Protocol: Treatment of Advanced Non-Small Cell Lung Cancer Using Atezolizumab		*Est. 04-Sep-202...
Revised: 1 Oct 2026		Actions
Pre-Chemo Metrics		
Alanine Aminotransferase Less Than or Equal		
salbutamol 5 mg, nebulized, q20min, PRN shortness of brea...	Planned	
Treatment Regimen		
Zero Time	0 hr	Planned
Select one atezolizumab option:		
Insert peripheral IV and saline lock prior to first administration of atezolizumab subcuta...		
atezolizumab (atezolizumab subcut - oncol... 1,875 mg, subcutaneous, once oncology, admini... Subcutaneous Injection: Inject into thigh. Observ...	0 min	
During treatment with subcutaneous atezolizumab, administer other subcutaneous drugs at alternate injection sites whenever possible		
atezolizumab (atezolizumab - oncology) 1,200 mg, IV, once oncology, administer over: 1 ... Day 1	0 min	

Versioning: Yes

Jira: CST-382696

Protocols: MYDARBD, MYDARCBDF, MYDARLDF, MYDARLD, MYDBLDFTE, MYDBLDFTI, LYDARCBDF, UMYISACARD, UMYISAPOMD

Cycles/PowerPlans:

ONCP MY MYDARBD Cycle 2
ONCP MY MYDARBD Cycles 3 and 4
ONCP MY MYDARBD Cycles 5 to 8
ONCP MY MYDARBD Cycles 9+
ONCP MY MYDARBD First Dose IV Cycle 1

ONCP MY MYDARBD First Dose IV Split Dosing Cycle 1
 ONCP MY MYDARBD First Dose Subcutaneous Cycle 1

ONCP MY MYDARCBDF Cycle 2
 ONCP MY MYDARCBDF Cycles 10+
 ONCP MY MYDARCBDF Cycles 3 to 6
 ONCP MY MYDARCBDF Cycles 7 to 9
 ONCP MY MYDARCBDF First Dose IV Cycle 1
 ONCP MY MYDARCBDF First Dose IV Split Dosing Cycle 1
 ONCP MY MYDARCBDF First Dose Subcutaneous Cycle 1

ONCP MY MYDARLDF Female of Childbearing Potential (FCBP) Cycle 2
 ONCP MY MYDARLDF Female of Childbearing Potential (FCBP) Cycles 3 to 6
 ONCP MY MYDARLDF Female of Childbearing Potential (FCBP) Cycles 7+
 ONCP MY MYDARLDF Female of Childbearing Potential (FCBP) First Dose IV Cycle 1
 ONCP MY MYDARLDF Female of Childbearing Potential (FCBP) First Dose Subcutaneous Cycle 1
 ONCP MY MYDARLDF Female of Childbearing Potential FCBP First Dose IV Split Dosing Cycle1
 ONCP MY MYDARLDF Non Childbearing Potential (NCBP) Cycle 2
 ONCP MY MYDARLDF Non Childbearing Potential (NCBP) Cycles 3 to 6
 ONCP MY MYDARLDF Non Childbearing Potential (NCBP) Cycles 7+
 ONCP MY MYDARLDF Non Childbearing Potential (NCBP) First Dose IV Cycle 1
 ONCP MY MYDARLDF Non Childbearing Potential (NCBP) First Dose IV Split Dosing Cycle 1
 ONCP MY MYDARLDF Non Childbearing Potential (NCBP) First Dose Subcutaneous Cycle 1

ONCP MY MYDARLD Female of Childbearing Potential (FCBP) Cycle 2
 ONCP MY MYDARLD Female of Childbearing Potential (FCBP) Cycles 3 to 6
 ONCP MY MYDARLD Female of Childbearing Potential (FCBP) Cycles 7+
 ONCP MY MYDARLD Female of Childbearing Potential (FCBP) First Dose IV Cycle 1
 ONCP MY MYDARLD Female of Childbearing Potential (FCBP) First Dose Subcutaneous Cycle 1
 ONCP MY MYDARLD Female of Childbearing Potential FCBP First Dose IV Split Dosing Cycle1
 ONCP MY MYDARLD Non Childbearing Potential (NCBP) Cycle 2
 ONCP MY MYDARLD Non Childbearing Potential (NCBP) Cycles 3 to 6
 ONCP MY MYDARLD Non Childbearing Potential (NCBP) Cycles 7+
 ONCP MY MYDARLD Non Childbearing Potential (NCBP) First Dose IV Cycle 1
 ONCP MY MYDARLD Non Childbearing Potential (NCBP) First Dose IV Split Dosing Cycle 1
 ONCP MY MYDARLD Non Childbearing Potential (NCBP) First Dose Subcutaneous Cycle 1

ONCP MY MYDBLDFTE Female of Childbearing Potential (FCBP) Consolidation Cycle 5
 ONCP MY MYDBLDFTE Female of Childbearing Potential (FCBP) Consolidation Cycle 6
 ONCP MY MYDBLDFTE Female of Childbearing Potential (FCBP) Daratumumab Restart Cycle 1
 ONCP MY MYDBLDFTE Female of Childbearing Potential (FCBP) Daratumumab Restart Cycle 2
 ONCP MY MYDBLDFTE Female of Childbearing Potential (FCBP) Induction Cycle 1
 ONCP MY MYDBLDFTE Female of Childbearing Potential (FCBP) Induction Cycle 2
 ONCP MY MYDBLDFTE Female of Childbearing Potential (FCBP) Induction Cycles 3 and 4
 ONCP MY MYDBLDFTE Female of Childbearing Potential (FCBP) Maintenance Cycles 7+
 ONCP MY MYDBLDFTE Female of Childbearing Potential Daratumumab Restart Cycles 3 to 6
 ONCP MY MYDBLDFTE Female of Childbearing Potential Daratumumab Restart Cycles 7+
 ONCP MY MYDBLDFTE Non Childbearing Potential (NCBP) Consolidation Cycles 5 and 6
 ONCP MY MYDBLDFTE Non Childbearing Potential (NCBP) Daratumumab Restart Cycle 1
 ONCP MY MYDBLDFTE Non Childbearing Potential (NCBP) Daratumumab Restart Cycle 2
 ONCP MY MYDBLDFTE Non Childbearing Potential (NCBP) Daratumumab Restart Cycles 3 to 6
 ONCP MY MYDBLDFTE Non Childbearing Potential (NCBP) Daratumumab Restart Cycles 7+

ONCP MY MYDBLDFTE Non Childbearing Potential (NCBP) Induction Cycle 1
 ONCP MY MYDBLDFTE Non Childbearing Potential (NCBP) Induction Cycle 2
 ONCP MY MYDBLDFTE Non Childbearing Potential (NCBP) Induction Cycles 3 and 4
 ONCP MY MYDBLDFTE Non Childbearing Potential (NCBP) Maintenance Cycles 7+

ONCP MY MYDBLDFTI Female of Childbearing Potential (FCBP) Cycle 1
 ONCP MY MYDBLDFTI Female of Childbearing Potential (FCBP) Cycle 2
 ONCP MY MYDBLDFTI Female of Childbearing Potential (FCBP) Cycles 3 and 4
 ONCP MY MYDBLDFTI Female of Childbearing Potential (FCBP) Cycles 5 to 8
 ONCP MY MYDBLDFTI Female of Childbearing Potential (FCBP) Cycles 9+
 ONCP MY MYDBLDFTI Non Childbearing Potential (NCBP) Cycles 1 and 2
 ONCP MY MYDBLDFTI Non Childbearing Potential (NCBP) Cycles 3 and 4
 ONCP MY MYDBLDFTI Non Childbearing Potential (NCBP) Cycles 5 to 8
 ONCP MY MYDBLDFTI Non Childbearing Potential (NCBP) Cycles 9+

ONCP LY LYDARCBDF Cycle 1
 ONCP LY LYDARCBDF Cycle 2
 ONCP LY LYDARCBDF Cycles 3 to 6
 ONCP LY LYDARCBDF Cycles 7+
 ONCP MY UMYISACARD Cycles 2+
 ONCP MY UMYISAPOMD Female of Childbearing Potential (FCBP) Cycles 2+
 ONCP MY UMYISAPOMD Non-Childbearing Potential (NCBP) Cycles 2+

Changes:

- For all PowerPlans in the Chemotherapy Phase, order comments to regularly scheduled pre-medications changed from '30 to 60 minutes' to '30 minutes'

Component	Dose	Details
ONCP MY MYDARBD First Dose IV Cycle 1 - Cycle 1, Chemotherapy (Day 1, 8, 15, 22) Future Pending *Est. 24-Sep-2026 08:00 PDT - 28 Days		
Link to Protocol: treatment of relapsed and refractory multiple myeloma with Daratumumab in Combination with Bortezomib and Dexamethasone		
Revised: 1 Oct 2026		
Pre-Medications		
☒	acetaminophen	650 mg, PO, once oncology, drug form: tab, Use Patient Supply 30 minutes prior to daratumumab, Days 1, 8, 15, 22
☐	loratadine	10 mg, PO, once oncology, drug form: tab, Use Patient Supply 30 minutes prior to daratumumab, Days 1, 8, 15, 22
☐	diphenhydramine	50 mg, PO, once oncology, drug form: cap, Use Patient Supply 30 minutes prior to daratumumab, Days 1, 8, 15, 22
☐	diphenhydramine	50 mg, IV, once oncology, administer over: 15 minute, drug form: inj 30 minutes prior to daratumumab, Days 1, 8, 15, 22
☒	montelukast	10 mg, PO, once oncology, drug form: tab, Use Patient Supply 30 minutes prior to daratumumab, Day 1
☐	montelukast	10 mg, PO, once oncology, drug form: tab, Use Patient Supply 30 minutes prior to daratumumab, Days 8, 15, 22

Component	Dose	Details
ONCP MY MYDARBD Cycle 2 - Cycle 2, Chemotherapy (Day 1, 8, 15, 22) Future Pending *Est. 24-Sep-2026 08:00 PDT - 28 Days		
Link to Protocol: treatment of relapsed and refractory multiple Myeloma with Daratumumab in Combination with Bortezomib and Dexamethasone		
Revised: 1 Oct 2026		
Pre-Medications		
☐	acetaminophen	650 mg, PO, once oncology, drug form: tab, Use Patient Supply 30 minutes prior to daratumumab, Days 1, 8, 15, 22
☐	loratadine	10 mg, PO, once oncology, drug form: tab, Use Patient Supply 30 minutes prior to daratumumab, Days 1, 8, 15, 22
☐	diphenhydramine	50 mg, PO, once oncology, drug form: cap, Use Patient Supply 30 minutes prior to daratumumab, Days 1, 8, 15, 22
☐	diphenhydramine	50 mg, IV, once oncology, administer over: 15 minute, drug form: inj 30 minutes prior to daratumumab, Days 1, 8, 15, 22
☐	montelukast	10 mg, PO, once oncology, drug form: tab, Use Patient Supply 30 minutes prior to daratumumab, Days 1, 8, 15, 22

- For all Cycle 2+ PowerPlans in the Chemotherapy Phase, under regularly scheduled pre-medications, acetaminophen order deselected

ONCP MY MYDARBD Cycle 2 - Cycle 2, Chemotherapy (Day 1, 8, 15, 22) Future Pending *Est. 24-Sep-2026 08:00 PDT - 28 Days

Link to Protocol: Treatment of Relapsed and Refractory Multiple Myeloma with Daratumumab in Combination with Bortezomib and Dexamethasone

Revised: 1 Oct 2026

Pre-Medications

☐	acetaminophen	650 mg, PO, once oncology, drug form: tab, Use Patient Supply
☐	lorazepam	10 mg, PO, once oncology, drug form: tab, Use Patient Supply

- For Prescription Phases in all Cycle 1 PowerPlans (Inpatient and Outpatient), order comments or special instructions for prednisone and dexamethasone updated to 'Take dose prior to daratumumab in Cycle 1 and take dose in the morning in subsequent cycles'

ONCP MY MYDARBD First Dose IV Cycle 1 - Cycle 1, Prescriptions Future Pending *Est. 24-Sep-2026 08:00 PDT

Select an order sentence

Ensure montelukast outpatient prescription is given to patient

Select one of the following. Refer to protocol for steroid dosing options:

☐	dexamethasone	40 mg, PO, qweek, Days 1, 8, 15, 22, Take dose prior to daratumumab in Cycle 1 and take dose in the morning in subsequent cycles, drug form: tab, dispense qty: 28 day
☐	prednisone	100 mg, PO, qweek, Days 1, 8, 15, 22, Take dose prior to daratumumab in Cycle 1 and take dose in the morning in subsequent cycles, drug form: tab, dispense qty: 28 day

ONCP MY MYDARBD First Dose IV Cycle 1 - Cycle 1, Prescriptions (Inpatient Use Only) Future Pending *Est. 24-Sep-2026 08:00 PDT

Select an order sentence

Ensure montelukast outpatient prescription is given to patient

Select one of the following. Refer to protocol for steroid dosing options:

☐	dexamethasone	40 mg, PO, qweek oncology, order duration: 4 doses or times, drug form: tab, Take dose prior to daratumumab in Cycle 1 and take dose in the morning in subsequent cycles. Medication is part of a combined IV/PO protocol. Days 1, 8, 15, 22
☐	prednisone	100 mg, PO, qweek oncology, order duration: 4 doses or times, drug form: tab, Take dose prior to daratumumab in Cycle 1 and take dose in the morning in subsequent cycles. Medication is part of a combined IV/PO protocol. Days 1, 8, 15, 22

- For Prescription Phases in all Cycle 2+ PowerPlans (Inpatient and Outpatient), order comments for prednisone and dexamethasone updated to 'Take dose in the morning'

ONCP MY MYDARBD Cycle 2 - Cycle 2, Prescriptions Future Pending *Est. 24-Sep-2026 08:00 PDT

Select an order sentence

Ensure montelukast outpatient prescription is given to patient

Select one of the following. Refer to protocol for steroid dosing options:

☐	dexamethasone	40 mg, PO, qweek, Days 1, 8, 15, 22, drug form: tab, dispense qty: 28 day
☐	prednisone	100 mg, PO, qweek, Days 1, 8, 15, 22, drug form: tab, dispense qty: 28 day

ONCP MY MYDARBD Cycle 2 - Cycle 2, Prescriptions (Inpatient Use Only) Future Pending *Est. 24-Sep-2026 08:00 PDT

Select an order sentence

Select one of the following. Refer to protocol for steroid dosing options:

☐	dexamethasone	40 mg, PO, qweek oncology, order duration: 4 doses or times, drug form: tab, Take dose in the morning. Medication is part of a combined IV/PO protocol. Days 1, 8, 15, 22
☐	prednisone	100 mg, PO, qweek oncology, order duration: 4 doses or times, drug form: tab, Take dose in the morning. Medication is part of a combined IV/PO protocol. Days 1, 8, 15, 22

- For all Cycle 2+ PowerPlans in the Chemotherapy Phase, under regularly scheduled Pre-Medications, acetaminophen order deselected

ONCP MY UMYISACARD Cycles 2+ - Cycle 2, Chemotherapy (Day 1, 8, 15) Future Pending *Est. 24-Sep-2026 08:00 PDT - 28 Days

Link to Protocol: Therapy of Multiple Myeloma using Carfilzomib and Dexamethasone and Isatuximab with or without Cyclophosphamide

Pre-Medications

☐	dexamethasone	mg, IV, once oncology, administer over: 15 minute, drug form: bag
☐	montelukast	10 mg, PO, once oncology, drug form: tab, Use Patient Supply
☐	acetaminophen	650 mg, PO, once oncology, drug form: tab, Use Patient Supply
☐	lorazepam	10 mg, PO, once oncology, drug form: tab, Use Patient Supply

Versioning: Y

Jira: CST-382221

Protocols: ULUAVPPAF and ULUAVPPAMI

Cycles/PowerPlans: All associated PowerPlans and Regimens

Changes:

- Irinotecan order comment under Prescriptions phase updated to: 'Mix with cold cranberry or grape juice...'

Component	Dose	Details
temozolomide (temozolomide - oncology)	100 mg/m ² , PO, as directed, Take once daily in the evening on Days 1 to 5 of each cycle. Take 60 minutes prior to irinotecan, drug form: cap, dr	Take 60 minutes prior to irinotecan. Apply standard dose. Dispense quantity = 1 cycle. Prescription is part of a combined IV/PO protocol.
irinotecan	90 mg/m ² , PO, as directed, Take once daily in the evening on days 1 to 5 of each cycle. Take 60 minutes after temozolomide, drug form: syringe	Take 60 minutes after temozolomide. Mix with cold cranberry or grape juice immediately prior to use. Dispense quantity = 1 cycle. Pharmacy to

- Irinotecan order comment under Prescriptions (Inpatient Use Only) phase updated to: 'Mix with cold cranberry or grape juice...'

Component	Dose	Details
temozolomide (temozolomide - oncology)	100 mg/m ² , PO, qHS, order duration: 5 doses or times, drug form: cap, Use Patient Supply	Take 60 minutes prior to irinotecan. Apply standard dose. Medication is part of a combined IV/PO protocol. Days 1 to 5
irinotecan (irinotecan - oncology)	90 mg/m ² , PO, qHS, order duration: 5 doses or times, drug form: syringe-oral, Use Patient Supply	Take 60 minutes after temozolomide. Mix with cold cranberry or grape juice immediately prior to use. Medication is part of a combined IV/PO p

Versioning: Y

Jira: CST-384037

Net New Protocols:

Net New Protocols:

- ONCP LY LYCLLACALV Pretreatment Plan
- ONCP LY LYCLLACALV Cycle 1 (PO)
- ONCP LY LYCLLACALV Cycle 2 (PO)
- ONCP LY LYCLLACALV High TLS Risk Ramp-Up Cycle 3 Week 1 (Inpatient)
- ONCP LY LYCLLACALV High TLS Risk Ramp-Up Cycle 3 Week 2 (Inpatient)
- ONCP LY LYCLLACALV High TLS Risk Ramp-Up Cycle 3 Weeks 3 to 5 (PO)
- ONCP LY LYCLLACALV High TLS Risk Ramp-Up Prescriptions Cycle 3 Weeks 1 to 5 (PO)
- ONCP LY LYCLLACALV Low/Moderate TLS Risk Ramp-Up Cycle 3 Weeks 1 to 5 (PO)
- ONCP LY LYCLLACALV Post Ramp-Up Cycles 4 to 14 (PO)

- ONCP LU LUAVPCDT Pretreatment Plan
- ONCP LU LUAVPCDT Cycles 1 to 4
- ONCP LU LUAVPCDT Cycle 5
- ONCP LU LUAVPCDT Cycle 6
- ONCP LU LUAVPCDT Cycles 7+
- ONCP LU LUAVPCDT Tremelimumab Retreatment Dose
- ONCP BR BRAJPEM6 Cycle 1
- ONCP BR BRAJPEM6 Cycles 2+
- ONCP LY LYMCABENDR Pretreatment Plan
- ONCP LY LYMCABENDR Cycles 1 to 5
- ONCP LY LYMCABENDR Cycle 6
- ONCP LY LYMCABENDR Cycles 7 to 14
- ONCP LY LYMCABENDR Cycle 15+
- ONCP BR BRAVLUENH Pretreatment Plan
- ONCP BR BRAVLUENH
- ONCP LU LUAVAMLA Pretreatment Plan
- ONCP LU LUAVAMLA Baseline Weight Less than 80 kg Cycle 1
- ONCP LU LUAVAMLA Baseline Weight Less than 80 kg Cycle 2+
- ONCP LU LUAVAMLA Baseline Weight 80 kg or more Cycle 1
- ONCP LU LUAVAMLA Baseline Weight 80 kg or more Cycle 2+
- ONCP LU LUAVAMI Pretreatment Plan
- ONCP LU LUAVAMI Baseline Weight Less than 80 kg Cycle 1
- ONCP LU LUAVAMI Baseline Weight Less than 80 kg Cycle 2+
- ONCP LU LUAVAMI Baseline Weight 80 kg or more Cycle 1
- ONCP LU LUAVAMI Baseline Weight 80 kg or more Cycle 2+
- ONCP LU LUAVPPDT Pretreatment Plan
- ONCP LU LUAVPPDT CISplatin Option Cycles 1 to 4
- ONCP LU LUAVPPDT CARBOplatin Option Cycles 1 to 4
- ONCP LU LUAVPPDT Cycle 5
- ONCP LU LUAVPPDT Cycle 6
- ONCP LU LUAVPPDT Cycles 7+
- ONCP LU LUAVPPDT Tremelimumab Retreatment Doses
- ONCP LU LUAVPGDT Pretreatment Plan
- ONCP LU LUAVPGDT CISplatin Option Cycles 1 to 4
- ONCP LU LUAVPGDT CARBOplatin Option Cycles 1 to 4
- ONCP LU LUAVPGDT Cycle 5
- ONCP LU LUAVPGDT Cycle 6
- ONCP LU LUAVPGDT Cycles 7+
- ONCP LU LUAVPGDT Tremelimumab Retreatment Doses
- ONCP LK LKAMLQMTN Pretreatment Plan
- ONCP LK LKAMLQMTN Cycle 1 (PO)
- ONCP LK LKAMLQMTN Cycle 2+ (PO)
- ONCP LK ULKAMLQUI (PO) Induction
- ONCP LK ULKAMLQUI (PO) Consolidation
- ONCP LK ULKAMLQUI (Inpatient)

Jira Ticket #	CST-387414, CST-387411, CST-385841, CST-385569, CST-384037, CST-382696, CST-382221 CST-385679, CST-385676, CST-384937, CST-384820, CST-384819, CST-382578, CST-382563, CST-380195, CST-380194, CST-374770, CST-374768
How-to questions?	http://cstcernerhelp.healthcarebc.ca
Need further support?	CST Cerner Phone Support: 1-844-214-7444